CN111699189B - 可用于治疗或预防与其相关的心力衰竭和障碍的β-3肾上腺素能受体的调节剂 - Google Patents

可用于治疗或预防与其相关的心力衰竭和障碍的β-3肾上腺素能受体的调节剂 Download PDF

Info

Publication number
CN111699189B
CN111699189B CN201880088219.8A CN201880088219A CN111699189B CN 111699189 B CN111699189 B CN 111699189B CN 201880088219 A CN201880088219 A CN 201880088219A CN 111699189 B CN111699189 B CN 111699189B
Authority
CN
China
Prior art keywords
phenyl
methyl
pyridin
dihydro
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880088219.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN111699189A (zh
Inventor
T-A·陈
B·乌尔曼
B·A·克莱默
Q-Q·T·杜
Y-J·申
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Publication of CN111699189A publication Critical patent/CN111699189A/zh
Application granted granted Critical
Publication of CN111699189B publication Critical patent/CN111699189B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880088219.8A 2017-12-06 2018-12-06 可用于治疗或预防与其相关的心力衰竭和障碍的β-3肾上腺素能受体的调节剂 Active CN111699189B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762595133P 2017-12-06 2017-12-06
US62/595,133 2017-12-06
PCT/US2018/064316 WO2019113359A1 (en) 2017-12-06 2018-12-06 Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto

Publications (2)

Publication Number Publication Date
CN111699189A CN111699189A (zh) 2020-09-22
CN111699189B true CN111699189B (zh) 2025-02-18

Family

ID=64744985

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880088219.8A Active CN111699189B (zh) 2017-12-06 2018-12-06 可用于治疗或预防与其相关的心力衰竭和障碍的β-3肾上腺素能受体的调节剂

Country Status (9)

Country Link
US (2) US11339172B2 (https=)
EP (1) EP3720858B1 (https=)
JP (1) JP7357617B2 (https=)
CN (1) CN111699189B (https=)
AR (1) AR114156A1 (https=)
ES (1) ES2953576T3 (https=)
MA (1) MA51015A (https=)
TW (1) TWI822713B (https=)
WO (1) WO2019113359A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA44037B1 (fr) * 2016-06-06 2020-03-31 Arena Pharm Inc Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
LT3483164T (lt) 2017-03-20 2020-05-11 Forma Therapeutics, Inc. Pirolpirolo kompozicijos kaip piruvato kinazės (pkr) aktyvatoriai
CN111699189B (zh) 2017-12-06 2025-02-18 艾尼纳制药公司 可用于治疗或预防与其相关的心力衰竭和障碍的β-3肾上腺素能受体的调节剂
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
EP3853206B1 (en) 2018-09-19 2024-04-10 Novo Nordisk Health Care AG Treating sickle cell disease with a pyruvate kinase r activating compound
HRP20251148T1 (hr) 2019-09-19 2025-11-21 Novo Nordisk Health Care Ag Pripravci koji aktiviraju piruvat-kinazu r (pkr)
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
US20250127773A1 (en) * 2021-08-09 2025-04-24 Arena Pharmaceuticals, Inc. Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure
WO2023026185A1 (en) * 2021-08-26 2023-03-02 Arena Pharmaceuticals, Inc. Modulators of the beta-3 adrenergic receptor for the treatment or prevention of renal cystic disease and cardiorenal syndrome
EP4699606A3 (en) 2021-10-06 2026-03-25 Arena Pharmaceuticals, Inc. Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017214002A1 (en) * 2016-06-06 2017-12-14 Arena Pharmaceuticals, Inc. Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451677A (en) * 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
FR2755439B1 (fr) * 1996-11-05 1998-12-24 Virbac Sa Derives aryloxypropanolamines, leur procede de preparation et leurs applications
AU2525801A (en) * 1999-12-17 2001-06-25 Sanofi-Synthelabo Phenoxypropanolamines, method for producing them and pharmaceutical compositionscontaining them
CN1469876A (zh) * 2000-10-20 2004-01-21 �Ʒ� α-芳基乙醇胺及其用作β-3肾上腺素能受体激动剂的用途
EP1833480A2 (en) * 2004-11-30 2007-09-19 Artesian Therapeutics, Inc. Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase
US20170231885A1 (en) 2014-10-14 2017-08-17 Sculpt B.V. Body Sculpting
CN111699189B (zh) 2017-12-06 2025-02-18 艾尼纳制药公司 可用于治疗或预防与其相关的心力衰竭和障碍的β-3肾上腺素能受体的调节剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017214002A1 (en) * 2016-06-06 2017-12-14 Arena Pharmaceuticals, Inc. Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto

Also Published As

Publication number Publication date
US11987588B2 (en) 2024-05-21
EP3720858A1 (en) 2020-10-14
EP3720858C0 (en) 2023-06-07
TW201925206A (zh) 2019-07-01
MA51015A (fr) 2021-04-21
ES2953576T3 (es) 2023-11-14
AR114156A1 (es) 2020-07-29
EP3720858B1 (en) 2023-06-07
WO2019113359A1 (en) 2019-06-13
CN111699189A (zh) 2020-09-22
JP2021505598A (ja) 2021-02-18
US20220396579A1 (en) 2022-12-15
TWI822713B (zh) 2023-11-21
US20200385395A1 (en) 2020-12-10
US11339172B2 (en) 2022-05-24
JP7357617B2 (ja) 2023-10-06

Similar Documents

Publication Publication Date Title
CN111699189B (zh) 可用于治疗或预防与其相关的心力衰竭和障碍的β-3肾上腺素能受体的调节剂
AU2021206809B2 (en) Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto
AU2013312931B2 (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
CN112638917A (zh) 作为激酶抑制剂的杂环化合物、包括该杂环化合物的组合物、及其使用方法
JP2022502484A (ja) キナーゼ阻害活性を有する芳香族複素環式化合物
HK40039344B (en) Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto
HK40039344A (en) Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto
WO2026026956A1 (zh) Tacc抑制剂化合物、药物组合物及其制备方法和应用
HK40046602A (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
HK40004811B (en) Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto
HK40004811A (en) Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto
HK40006318A (en) Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant